JPMorgan Chase & Co. Reduces Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

JPMorgan Chase & Co. cut its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 11.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,643,755 shares of the company's stock after selling 357,642 shares during the period. JPMorgan Chase & Co. owned about 1.29% of Taysha Gene Therapies worth $4,574,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Taysha Gene Therapies by 4.5% during the third quarter. State Street Corp now owns 3,469,068 shares of the company's stock worth $6,973,000 after purchasing an additional 150,647 shares during the period. Barclays PLC increased its stake in shares of Taysha Gene Therapies by 356.0% during the third quarter. Barclays PLC now owns 247,280 shares of the company's stock worth $513,000 after purchasing an additional 193,046 shares during the period. Geode Capital Management LLC increased its stake in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company's stock worth $7,163,000 after purchasing an additional 682,273 shares during the period. Franklin Resources Inc. bought a new position in shares of Taysha Gene Therapies during the third quarter worth approximately $201,000. Finally, Quantum Private Wealth LLC grew its position in Taysha Gene Therapies by 3.6% during the fourth quarter. Quantum Private Wealth LLC now owns 794,976 shares of the company's stock worth $1,375,000 after buying an additional 27,360 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on TSHA. Needham & Company LLC reiterated a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Chardan Capital reaffirmed a "buy" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA traded up $0.01 during trading on Thursday, hitting $1.83. 313,595 shares of the company's stock traded hands, compared to its average volume of 2,691,854. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock has a market capitalization of $374.23 million, a price-to-earnings ratio of 2.88 and a beta of 0.96. The business has a 50 day moving average of $1.54 and a 200-day moving average of $1.80.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. As a group, equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.